WTX-330 is being tested in a Phase 1 clinical trial (NCT05678998) and is Werewolf's second clinical program to utilize the INDUKINE design, aiming to deliver potent immune mechanisms to tumors ...

is currently being evaluated in a Phase 1 clinical trial: NCT05678998. This is Werewolf’s second clinical program to validate the INDUKINE design, delivering potent immune mechanisms to the ...

is currently being evaluated in a Phase 1 clinical trial: NCT05678998. This is Werewolf’s second clinical program to validate the INDUKINE design, delivering potent immune mechanisms to the ...

Werewolf continues to progress the ongoing Phase 1/1b clinical trial evaluating WTX-124 as a monotherapy and in combination with pembrolizumab. Following the selection of 18 mg WTX-124 ...

At least 11 babies have grown hair all over their bodies after their parents used FDA-approved medications to treat baldness.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL), a biopharmaceutical company specializing in immune system-stimulating therapeutics for cancer treatment, has announced new clinical and preclinical data at ...

The trial results revealed that WTX-330 has shown ... justifying a Buy recommendation for Werewolf Therapeutics’ stock. According to TipRanks, Y. Maldonado is a 4-star analyst with an average ...

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.

Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be ...